Abstract: A method of operating a network of plants comprising a blast furnace, a direct reduction furnace, a CO2 conversion unit wherein blast furnace top gas is subjected to a CO2 conversion step to produce a liquid carbon product which is injected into the direct reduction furnace.

Abstract: A method for manufacturing direct reduced iron wherein oxidized iron is reduced in a direct reduction furnace by a reducing gas, the direct reduction furnace including a reduction zone, a transition zone and a cooling zone, a carbon-bearing liquid being injected below the reduction zone.

Abstract: A method for manufacturing direct reduced iron wherein oxidized iron is reduced in a direct reduction furnace by a reducing gas, the oxidized iron being first mixed with biochar to form a solid compound and the solid compound is charged into the direct reduction furnace.

Abstract: A method for manufacturing direct reduced iron wherein iron ore is reduced in a direct reduction furnace by a reducing gas, the reducing gas exiting the furnace through the top as a top reduction gas. The top reduction gas is captured and at least partly subjected to a CO2 recovery step during which it is divided into two streams, a CO2-rich stream and a CO2-poor stream. The CO2-rich stream is subjected to an alkanol production step to produce an alkanol product.

Abstract: A method for manufacturing Direct Reduced Iron wherein iron ore is reduced in a DRI shaft by a reducing gas including hydrogen obtained by extraction from coke oven gas through a hydrogen separation unit, the remaining part of such coke oven gas being at least partly injected in the transition section of said DRI shaft to set the carbon amount of said Direct Reduced Iron from 0.5 to 3 wt. % and a DRI manufacturing equipment including a DRI shaft (1) and a hydrogen separation unit (5), wherein said hydrogen separation unit (5) inlet is connected to a coke oven gas supply (6) and includes a first outlet connected to the DRI shaft to inject hydrogen separated from said coke oven gas and a second outlet connected to the transition section of said DRI shaft (1) to inject at least part of the remaining part of such coke oven gas.

Abstract: A method for manufacturing Direct Reduced Iron wherein iron ore is reduced in a DRI shaft by a reducing gas including hydrogen obtained by thermal cracking of methane inside a plasma torch, the reducing gas further including top gas coming from the DRI shaft and a DRI manufacturing equipment including a DRI shaft (1) and a plasma torch (40), wherein the plasma torch is connected on one side to a methane supply (41) and, on the other side, to the DRI shaft (1), the DRI shaft being provided with a recycling loop allowing to inject its top gas back in the DRI shaft.

Abstract: Described herein are methods and systems for preventing a glycemic event. One or more improved deep-learning models for predicting glycemic events may receive current blood glucose data and other physiological data from associated with a patient. The one or more models may determine one or more future blood glucose values and whether or not the one or more future blood glucose values satisfy one ore more thresholds associated with one or more glycemic events (e.g., hypoglycemia and/or hyperglycemia). If the one or more future blood glucose values satisfy the one or more thresholds, one or more actions may be taken (e.g., administration of insulin).

Abstract: Techniques and methods are disclosed for providing improved and consistent navigation within a mobile shopping application. A default graphical user interface may be provided at a display of a user device. In response to a navigation request at the default graphical user interface, the application can enter a store mode for a separate specialty store within the application. While in the store mode, the application can present a subsequent graphical user interface that overlays the default graphical user interface. The subsequent graphical user interface can be configured using data conforming to a graphical interface specification. The graphical interface specification may also include rules for determining which navigation requests properly enter and leave the store mode.

Abstract: Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Abstract: Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONY) using the inhalation formulations.

Abstract: The present invention is directed to a food product prepared by soaking a predetermined quantity of chia seeds in liquid under a dark environment and under a temperature in a range of 32 degrees Fahrenheit to 40 degrees Fahrenheit for a predetermined period to obtain pearls of chia seeds; and adding the pearls of chia seeds to a food product. The food product is bubble drink without tapioca starch.

Abstract: The present disclosure provides for palonosetron formulations, such as aerosol formulations of palonosetron for pulmonary delivery. Also provided are uses of the formulation, such as reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, or surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Abstract: The present disclosure provides for palonosetron formulations, such as aerosol formulations of palonosetron for pulmonary delivery. Also provided are uses of the formulation, such as reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, or surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONY) using the inhalation formulations.

Abstract: Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Abstract: Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Abstract: The present disclosure provides for palonosetron formulations, such as aerosol formulations of palonosetron for pulmonary delivery. Also provided are uses of the formulation, such as reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, or surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Abstract: Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Abstract: Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.